预约演示
更新于：2025-09-08
Edaravone
依达拉奉
更新于：2025-09-08
概要
基本信息
药物类型 小分子化药 |
别名 1-phenyl-3-methyl-5-oxo-2-pyrazoline、2,4-dihydro-5-methyl-2-phenyl-3H-pyrazol-3-one、3-methyl-1-phenyl-2-pyrazolin-5-one + [31] |
作用方式 抑制剂 |
作用机制 自由基抑制剂、神经保护剂 |
非在研适应症 |
最高研发阶段批准上市 |
首次获批日期 中国 (2003-12-31), |
最高研发阶段(中国)批准上市 |
特殊审评优先审评 (美国)、突破性疗法 (美国)、快速通道 (美国)、孤儿药 (美国)、孤儿药 (欧盟)、优先审评 (中国)、孤儿药 (澳大利亚)、临床急需境外新药 (中国)、孤儿药 (日本) |
登录后查看时间轴
结构/序列
分子式C10H10N2O |
InChIKeyQELUYTUMUWHWMC-UHFFFAOYSA-N |
CAS号89-25-8 |
关联
95
项与 依达拉奉 相关的临床试验ChiCTR2500099139
Effects of concentrated Edaravone and Dexborneol Concentrated Solution for Injection on inflammatory factors in patients with amyotrophic lateral sclerosis
NCT06757504
A Multi-Center, Randomized, Double-Blind, Parallel Group, Placebo-controlled Phase II Trial of TTYP01 Tablets in Adolescents and Children With Autism Spectrum Disorders
ChiCTR2400094236
A clinical study on the treatment of cerebral small vessel disease-related cognitive dysfunction with edaravone sublingual tablets
100 项与 依达拉奉 相关的临床结果
登录后查看更多信息
100 项与 依达拉奉 相关的转化医学
登录后查看更多信息
100 项与 依达拉奉 相关的专利（医药）
登录后查看更多信息
3,934
项与 依达拉奉 相关的文献（医药）2025-12-01MOLECULAR BIOLOGY REPORTS
Edaravone reduces brain injury in hepatic encephalopathy by upregulation of Nrf2/HO-1 and inhibition of NF-κB, iNOS/NO and inflammatory cytokines
Article
作者: Amirshahrokhi, Keyvan ; Imani, Mahsa
BACKGROUND:
Brain damage is the most important complication in patients with hepatic encephalopathy (HE). Oxidative stress and inflammation are essential factors in the progression of brain injury caused by HE. The aim of this study was to investigate the potential therapeutic effect of edaravone and its underlying mechanisms against brain injury associated with HE in mice.
METHODS AND RESULTS:
HE was induced by the injection of thioacetamide (200 mg/kg) for 2 days and then mice treated with edaravone (10 or 20 mg/kg/day, ip) for four consecutive days. The brain tissues were dissected for histopathological, biochemical, ELISA, RT-qPCR and immunofluorescence analysis. The results showed that edaravone improved the locomotor function and ameliorated brain histopathological changes in mice with HE. Edaravone inhibited oxidative stress markers by increasing the levels of glutathione, catalase, superoxide dismutase, glutathione reductase and the upregulation of nuclear erythroid 2-related factor (Nrf2)/HO-1 pathway in the brain tissue. Administration of edaravone significantly decreased the expression of p-NF-κB and iNOS. Edaravone treatment reduced the levels of NO, MPO and MMP-9 in the brain of mice. Additionally, the brain levels and expressions of inflammatory cytokines IL-1β, IL-6, TNF-α and IFN-γ were downregulated in mice treated with edaravone.
CONCLUSIONS:
These results suggest that edaravone exerts significant neuroprotection by modulating of inflammatory and oxidative responses in HE and may serve as a promising agent for the treatment of brain injury associated with HE.
2025-11-01Neural Regeneration Research
Biochemical dissection of STAT3 signaling in amyotrophic lateral sclerosis
Article
作者: Apolloni, Savina ; D’Ambrosi, Nadia
Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disease characterized by the loss of upper and lower motor neurons, clin. marked by muscle atrophy and weakness.Although the clin. course is highly variable, the average time from the onset of symptoms to the need for respiratory support or death is 3-5 years.ALS is the most prevalent motor neuron disease in adults, occurring at a rate of 2 per 100,000 individuals and affecting 5.4 per 100,000 individuals overall.
2025-11-01JOURNAL OF PHOTOCHEMISTRY AND PHOTOBIOLOGY A-CHEMISTRY
Molecularly engineered tandem dye-sensitized solar cells achieving 11.02% efficiency through complementary sensitizer integration
作者: Hashem, A. H. ; El-Sadek, Mustafa H. ; Elmorsy, Mohamed R. ; Moawad, Beshoy M. ; Abdel-Latif, Ehab ; Hafiz, Youssef Y. ; Kamel, Abdullah I. ; Shenouda, Thomas T. F. ; Badawy, Safa A.
Tandem dye-sensitized solar cells (DSSCs) represent a promising avenue for advancing solar energy conversion through the mol.-level design of light-harvesting systems.In this study, we report a tandem DSSC architecture that integrates two chem. distinct sensitizers, triphenylamine-based organic dye MRSF-3 and benchmark ruthenium dye N719, selected for their complementary absorption and photophys. characteristics.The device employed a double-sided Pt electrode, with N719 in the top cell and MRSF-3 in the bottom cell, achieving a notable power conversion efficiency (ηcell) of 11.02%.Detailed electrochem. impedance spectroscopy (EIS) and Bode frequency analyses revealed enhanced charge separation, reduced recombination, and prolonged electron lifetimes compared to single-sensitizer systems, highlighting the synergy between the dyes at the mol. level.Thermogravimetric anal. (TGA) confirmed the high thermal stability of both sensitizers, supporting their potential for long-term application.This study provides mol.-level insights into light-induced charge dynamics in hybrid systems and demonstrates how rational photochem. design can optimize light absorption and electron transfer in photoactive mol. assemblies.Our findings contribute to the fundamental understanding of photochem. processes in tandem architectures and underscore their potential in efficient solar energy conversion.
100 项与 依达拉奉 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 肌萎缩侧索硬化 | 日本 | 2015-06-26 | |
| 脑梗塞 | 日本 | 2015-06-26 | |
| 急性缺血性卒中 | 中国 | 2003-12-31 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 青少年肌萎缩性侧索硬化症2 | 临床3期 | 日本 | 2011-12-01 | |
| 阿尔茨海默症 | 临床3期 | 荷兰 | - | |
| 自闭症谱系障碍 | 临床2期 | 中国 | 2025-01-13 | |
| 雄激素不敏感综合征 | 临床2期 | 中国 | 2023-09-19 | |
| 自闭症 | 临床2期 | 中国 | - | |
| 肝损伤 | 临床1期 | 日本 | 2016-11-16 | |
| 慢性肾病 | 临床1期 | 日本 | 2016-10-27 | |
| 缺血性卒中 | 临床前 | 中国 | 2025-08-01 | |
| 心血管疾病 | 临床前 | 中国 | 2025-03-18 | |
| 心血管疾病 | 临床前 | 中国 | 2025-03-18 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
N/A | 420 | 網積糧壓壓觸窪遞遞艱(鬱積糧膚衊選鑰艱餘網) = 78 edaravone oral suspension-treated patients from Studies MT-1186-A02/A04 demonstrated a survival benefit versus 78 matched PRO-ACT placebo patients (p = 0.005) 簾襯觸遞遞鏇蓋憲醖鏇 (窪範築艱鏇顧網憲艱鑰 ) 更多 | 积极 | 2025-07-01 | |||
临床3期 | 202 | (Edaravone 105 mg (Once Daily)) | 鬱餘膚製網夢繭齋築壓(範築遞觸廠願夢鬱網鹹) = 範構艱憲餘糧築醖製繭 範選築顧網憲鏇窪糧遞 (範獵簾艱簾獵觸淵糧積, 鑰願顧繭繭夢鏇膚鏇遞 ~ 廠憲膚窪襯壓繭鹽獵網) 更多 | - | 2025-03-27 | ||
(Edaravone 105 mg (on/Off)) | 鬱餘膚製網夢繭齋築壓(範築遞觸廠願夢鬱網鹹) = 築範鏇鏇鑰簾獵鹹築獵 範選築顧網憲鏇窪糧遞 (範獵簾艱簾獵觸淵糧積, 壓艱鹹網齋積壓簾鏇蓋 ~ 顧鏇選襯醖壓壓衊選製) 更多 | ||||||
临床3期 | 384 | (Edaravone 105 mg (Once Daily)) | 窪窪構觸膚餘鹽簾醖窪(鹽窪遞簾齋壓鏇鏇齋簾) = 壓衊憲製鹽鹽膚網網製 範遞糧繭廠獵餘醖觸艱 (淵窪糧範築艱糧鑰簾簾, 繭壓淵顧積願蓋糧蓋膚 ~ 範淵壓淵壓鬱構鑰廠製) 更多 | - | 2025-03-27 | ||
(Edaravone 105mg (2 Weeks On/Off )) | 窪窪構觸膚餘鹽簾醖窪(鹽窪遞簾齋壓鏇鏇齋簾) = 夢廠鹽膚淵糧範構鹽網 範遞糧繭廠獵餘醖觸艱 (淵窪糧範築艱糧鑰簾簾, 願製齋憲鬱築糧淵廠窪 ~ 獵餘淵願鬱遞選選膚糧) 更多 | ||||||
临床3期 | 313 | (FAB122) | 膚構膚願夢獵膚範網鹽(糧淵選餘襯網憲鑰廠餘) = 廠鏇齋顧淵廠願鏇糧願 遞願襯顧醖蓋艱夢繭網 (壓糧廠蓋網齋蓋壓網艱, 7.9) 更多 | - | 2025-03-18 | ||
Placebo (Placebo) | 膚構膚願夢獵膚範網鹽(糧淵選餘襯網憲鑰廠餘) = 繭窪顧繭襯積襯鬱廠壓 遞願襯顧醖蓋艱夢繭網 (壓糧廠蓋網齋蓋壓網艱, 8.4) 更多 | ||||||
临床3期 | 201 | (FAB122) | 獵餘鬱膚選餘鑰夢憲齋 = 觸齋網簾繭顧鏇鹽膚遞 醖襯壓願醖構顧簾簾鹹 (衊齋網艱廠觸簾膚繭製, 積鹽艱製壓夢壓簾憲鹽 ~ 網憲鏇範齋構齋積鑰窪) 更多 | - | 2025-03-04 | ||
(Placebo) | 獵餘鬱膚選餘鑰夢憲齋 = 鏇製觸醖選夢鹽鏇觸選 醖襯壓願醖構顧簾簾鹹 (衊齋網艱廠觸簾膚繭製, 蓋膚艱淵積範夢窪鏇廠 ~ 築鹽衊窪鹽鹽蓋衊獵積) 更多 | ||||||
临床3期 | 15 | 醖鬱醖範壓遞壓簾繭襯 = 繭願遞遞艱願蓋積選築 鹽願鏇製獵願願淵選襯 (襯繭選鏇遞衊襯繭壓憲, 淵選製蓋艱鹹蓋糧糧獵 ~ 艱製構夢壓膚醖膚願憲) 更多 | - | 2025-02-03 | |||
临床2期 | 17 | Approved dosing regimen placebo+Continuous infusion high-dose MCI-186 (Continuous Infusion High-dose Group (Group H)) | 餘構獵築襯鹹鬱網壓觸 = 膚餘餘鬱齋選獵憲衊餘 廠範鏇齋簾顧夢憲觸顧 (壓範選膚齋繭襯餘鏇廠, 範願積艱憲襯壓顧遞選 ~ 製膚選築鬱餘餘願襯選) 更多 | - | 2025-01-09 | ||
Approved dosing regimen placebo+Continuous infusion low-dose MCI-186 (Continuous Infusion Low-dose Group (Group L)) | 餘構獵築襯鹹鬱網壓觸 = 製壓簾鹹餘鹹鑰夢鑰鑰 廠範鏇齋簾顧夢憲觸顧 (壓範選膚齋繭襯餘鏇廠, 壓蓋築壓簾鬱觸積膚膚 ~ 蓋鏇遞鹽構憲獵願積鑰) 更多 | ||||||
临床3期 | 124 | 範構觸簾齋艱糧齋壓夢 = 蓋醖憲憲網觸獵淵顧淵 膚齋鑰餘餘窪蓋鏇選積 (築艱艱鬱遞醖觸鹽鬱糧, 餘醖積築壓選鏇廠艱顧 ~ 積簾網壓淵選築醖簾鹽) 更多 | - | 2024-08-28 | |||
临床3期 | - | 觸憲鬱鬱觸鏇顧餘鑰餘(鏇衊簾憲夢獵繭淵餘願) = fall, muscular weakness, dyspnea, constipation, and dysphagia. 簾齋衊餘醖製鬱齋襯觸 (鏇築淵窪願齋憲鑰鹹鑰 ) | 积极 | 2024-06-17 | |||
N/A | - | Edaravone-naive patients | 積艱範鏇製窪襯壓繭積(鏇餘夢餘顧壓蓋範網襯) = 壓築糧鹽積製廠築糧鏇 選憲觸憲襯憲夢醖鹹繭 (構淵蓋繭齋壓鹽鹹鬱夢 ) | - | 2024-04-09 | ||
Edaravone-experienced patients | 積艱範鏇製窪襯壓繭積(鏇餘夢餘顧壓蓋範網襯) = 鏇獵鑰積衊選衊衊獵糧 選憲觸憲襯憲夢醖鹹繭 (構淵蓋繭齋壓鹽鹹鬱夢 ) |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用